Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Radiation Oncology
•
Thoracic Malignancies
Do you use an LAD constraint in the setting of BID thoracic radiation for SCLC?
Related Questions
In resected N2 NSCLC, what nodal pathologic characteristics prompt you to recommend PORT?
Would you consider omitting concurrent chemoradiation for a patient with stage III EGFR-mutant NSCLC and initiating treatment with osimertinib instead?
In a patient who underwent cryoablation for early NSCLC, is there a role for giving preemptive further local therapy?
What radiation treatment volume would you include in chemoradiation given for perihilar lymph node recurrence after surgical resection and mediastinal lymph node dissection for NSCLC?
What dose contraints do use for the pulmonary artery and vein when treating with a lung lesion with SBRT?
Do you recommend consolidation immunotherapy after SBRT or surgery and chemo for T1-T2N0 SCLC?
Would you offer empiric lung SBRT for two growing FDG-avid lung lesions in a patient with severe COPD on oxygen?
Do you restrict the dose rate during treatment delivery to a pacemaker in addition to limiting the Dmax?
Does receipt of chemoimmunotherapy for LS-SCLC impact your recommendation for PCI?
In ES-SCLC presenting with extensive brain metastases, how do you time whole brain radiation after the first cycle of chemotherapy has already been delivered?
